MRK · News · 20260805N
Acquisition / Partnership / Divestiture
Merck & Co., Inc. · 2026-08-05 · Importance 71 · Surprise 60 · In source text
Merck recorded a $5.7 billion charge related to its acquisition of Terns Pharmaceuticals in the second quarter of 2026. The charge reduced GAAP diluted earnings per share by $2.31 and contributed to a GAAP net loss of $1.34 billion, or $0.54 per share. The transaction also produced a non-GAAP loss of $0.13 per share after acquisition-related costs. Merck cut its full-year profit guidance because of the Terns acquisition charge while retaining a higher sales outlook.
Key facts
- Merck posted a GAAP net loss of $1.34 billion in Q2 2026 and adjusted loss of $0.13 per share, primarily due to a $5.7 billion charge from the Terns Pharmaceuticals acquisition. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -34.3% | Merck posted a GAAP net loss of $1.34 billion in Q2 2026 and adjusted loss of $0.13 per share, primarily due to a $5.7 billion charge from… |
| net_income | negative | realized | — | Merck posted a GAAP net loss of $1.34 billion in Q2 2026 and adjusted loss of $0.13 per share, primarily due to a $5.7 billion charge from… |